BANK VONTOBEL/CALL/NOVO NORDISK ADR B/190/0.1/17.01.25 | Market Closed - Deutsche Boerse AG 11:32:32 29/05/2024 pm IST | ||
| 0.184 EUR | -6.60% |
|
| Current month | -23.33% | ||
| 1 month | -14.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 29/24/29 | 0.184 | -6.60% |
| 28/24/28 | 0.197 | -2.48% |
| 27/24/27 | 0.202 | -13.68% |
| 24/24/24 | 0.234 | +0.86% |
| 23/24/23 | 0.232 | +12.08% |
Delayed Quote Deutsche Boerse AG
Last update May 29, 2024 at 11:32 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD0JWF |
| ISIN | DE000VD0JWF3 |
| Date issued | 19/02/2024 |
| Strike | 190 $ |
| Maturity | 17/01/2025 (233 Days) |
| Parity | 10 : 1 |
| Emission price | 0.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.55 € |
|---|---|
| Lowest since issue | 0.147 € |
| Spread | 0.01 € |
| Spread % | 5.21% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
911.5
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.25%
- Stock Market
- Warrants
- Warrant
